Pediatric Anidulafungin 

 

This reference library was created for the community of providers who care for children with these illnesses. It was developed to assist clinicians in understanding, diagnosing and treating pediatric invasive fungal infections. The library links to important references within each category but is not meant to be comprehensive. 

 

Return to Library Home

 

 

 

 

 

 

 

 

 

 

International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA.   Tel: 919-668-4847 Email: PFNContracts@duke.edu

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

Benjamin DK Jr et al. Antimicrob Agents Chemother. 2006 Feb;50(2):632-8.

Invasive fungal infections in infants-focus on anidulafungin. 

Wilke MH. Clin Med Insights Pediatr. 2013 Feb 7;7:7-11.

Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. 

Cohen-Wolkowiez M et al. Clin Pharmacol Ther. 2011 May;89(5):702-7.

Anidulafungin—challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies

Alebic-Kolabah T et al. Anal Bioanal Chem. 2012 Oct;404(6-7):2043-55.

Anidulafungin: Is it a promising option in the treatment of pediatric invasive fungal infections?

Tapisiz A. Expert Rev Anti Infect Ther. 2011 Mar;9(3):339-46.

Pharmacology and antifungal properties of anidulafungin, a new echinocandin.

Estes KE et al. Pharmacotherapy. 2009 Jan;29(1):17-30.

Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. 

Varisco BM et al. Ann Pharmacother. 2009 Nov;43(11):1907-10.